Delving into the Latest Updates on S15-4E6A with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms-

Target

Siglec-15

Action

inhibitors

Mechanism

Siglec-15 inhibitors(Sialic acid-binding Ig-like lectin 15 inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Adenocarcinoma of Lung

Inactive Indication-

Originator Organization

Nanjing Medical University

Active Organization

Nanjing Medical University

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

In the present study, we first constructed and characterized a chimeric S15-specific monoclonal antibody (S15-4E6A). Then, the antitumor effectiveness and modulatory role of S15-4E6A in macrophages (mφs) were explored in vitro and in vivo. Finally, the underlying mechanism by which S15mAb inhibits LUAD was preliminarily explored.

RESULTS:

The results demonstrated the successful construction of S15-4E6A, and S15-4E6A exerted an efficacious tumor-inhibitory effect on LUAD cells and xenografts. S15-4E6A could promote M1-mφ polarization while inhibiting M2-mφ polarization, both in vitro and in vivo.

CONCLUSIONS:

S15-based immunotherapy that functions by modulating mφ polarization may be a promising strategy for the treatment of S15-positive LUAD.

100 Deals associated with S15-4E6A

Login to view more data